Probi AB
Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, Sweden, the Middle East, Africa, Asia Pacific, and internationally. The company conducts research primarily in the fields of mental, digestive, immune, bone, oral, children's, women's, and senior health, as well as iron absorption. It provides dietary … Read more
Market Cap & Net Worth: Probi AB (PROB)
Probi AB (ST:PROB) has a market capitalization of $353.46 Million (Skr3.97 Billion) as of March 18, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #17969 globally and #172 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Probi AB's stock price Skr348.00 by its total outstanding shares 11394100 (11.39 Million).
Probi AB Market Cap History: 2015 to 2025
Probi AB's market capitalization history from 2015 to 2025. Data shows growth from $131.30 Million to $353.46 Million (10.31% CAGR).
Probi AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Probi AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.33x
Probi AB's market cap is 0.33 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
12.18x
Probi AB's market cap is 12.18 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $131.30 Million | $215.98 Million | $49.04 Million | 0.61x | 2.68x |
| 2016 | $470.33 Million | $443.69 Million | $108.57 Million | 1.06x | 4.33x |
| 2017 | $336.99 Million | $612.24 Million | $69.09 Million | 0.55x | 4.88x |
| 2018 | $356.81 Million | $604.12 Million | $76.25 Million | 0.59x | 4.68x |
| 2019 | $220.03 Million | $626.19 Million | $85.89 Million | 0.35x | 2.56x |
| 2020 | $419.92 Million | $717.16 Million | $92.69 Million | 0.59x | 4.53x |
| 2021 | $396.48 Million | $658.18 Million | $83.14 Million | 0.60x | 4.77x |
| 2022 | $204.44 Million | $618.28 Million | $40.62 Million | 0.33x | 5.03x |
| 2023 | $204.87 Million | $627.69 Million | $16.82 Million | 0.33x | 12.18x |
Competitor Companies of PROB by Market Capitalization
Companies near Probi AB in the global market cap rankings as of March 18, 2026.
Key companies related to Probi AB by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Probi AB Historical Marketcap From 2015 to 2025
Between 2015 and today, Probi AB's market cap moved from $131.30 Million to $ 353.46 Million, with a yearly change of 10.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr353.46 Million | -0.29% |
| 2024 | Skr354.47 Million | +73.02% |
| 2023 | Skr204.87 Million | +0.21% |
| 2022 | Skr204.44 Million | -48.44% |
| 2021 | Skr396.48 Million | -5.58% |
| 2020 | Skr419.92 Million | +90.84% |
| 2019 | Skr220.03 Million | -38.33% |
| 2018 | Skr356.81 Million | +5.88% |
| 2017 | Skr336.99 Million | -28.35% |
| 2016 | Skr470.33 Million | +258.22% |
| 2015 | Skr131.30 Million | -- |
End of Day Market Cap According to Different Sources
On Feb 11th, 2026 the market cap of Probi AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $353.46 Million USD |
| MoneyControl | $353.46 Million USD |
| MarketWatch | $353.46 Million USD |
| marketcap.company | $353.46 Million USD |
| Reuters | $353.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.